Figure 4.
Meta-analysis and TSA results of blood pressure-related indicators in dorzagliatin vs. placebo in the treatment of T2DM. (A) Meta-analysis and TSA results of SBP in dorzagliatin vs. placebo in the treatment of T2DM. (B) Meta-analysis and TSA results of DBP in dorzagliatin vs. placebo in the treatment of T2DM.
